Which specific laboratory tests should be ordered for a newborn with subcutaneous fat necrosis?

Laboratory Testing for Subcutaneous Fat Necrosis of the Newborn

Order an initial ionized calcium level immediately upon clinical suspicion of SCFN, then monitor ionized calcium weekly for the first 3 months of life, as hypercalcemia occurs in 100% of monitored infants and can be life-threatening. 1

Essential Initial Laboratory Orders

Calcium Monitoring (Priority #1)

• Ionized calcium is the critical test—order this first when SCFN is suspected 1
• Total serum calcium should also be obtained 2, 3
• Hypercalcemia develops in 70.5–100% of cases where calcium is monitored 1, 4
• Peak calcium levels typically occur within the first 28 days of life (59% of cases), but hypercalcemia can develop up to 7 weeks after SCFN onset 1, 5

Additional Baseline Laboratory Tests

• Parathyroid hormone (PTH): Suppressed in 89.3% of hypercalcemic cases 4
• Platelet count: Mean lowest platelet count is significantly lower in SCFN patients (108 ± 55 × 10⁹/L) 2
• Electrolytes: Check for hypomagnesemia, hypokalemia 3
• Triglycerides: Hypertriglyceridemia can occur (2.6 mmol/L reported) 3
• Renal function: BUN and creatinine to assess for acute kidney injury 1

Monitoring Protocol by Calcium Level

Asymptomatic with Ionized Calcium <1.5 mmol/L

• Weekly ionized calcium monitoring for 3 months 1
• No infants with peak ionized calcium <1.5 mmol/L developed complications in the largest retrospective series 1
• Discontinue monitoring after 3 months if hypercalcemia has not developed, as no patients developed hypercalcemia after this timepoint 1

Ionized Calcium 1.5–1.6 mmol/L

• Twice-weekly ionized calcium monitoring 1
• 62% of infants had peak levels in this range 1
• Monitor for clinical symptoms: lethargy, poor feeding, vomiting, constipation 1, 2

Ionized Calcium >1.6 mmol/L or Symptomatic Hypercalcemia

• Daily ionized calcium monitoring 1
• Renal ultrasound to evaluate for nephrocalcinosis 1, 3
• Consider hospitalization for severe or symptomatic cases 1, 2
• Coordinate care with pediatric endocrinology or nephrology 1

Imaging Studies

Renal Ultrasound Indications

• Order when ionized calcium >1.6 mmol/L 1
• Order for any symptomatic hypercalcemia 1
• Order if hypercalcemia persists >6 months 1
• Nephrocalcinosis developed in 2 of 32 infants (6.3%) in the largest series 1

Skin Ultrasound (Optional)

• Can confirm diagnosis when clinical examination is equivocal 6
• Shows characteristic subcutaneous changes without ionizing radiation 6
• Not required for diagnosis but helpful to differentiate from other soft tissue pathology 6

Diagnostic Confirmation

Histopathology (When Needed)

• Fine-needle aspiration cytology shows necrotic fat with characteristic radially-oriented, refractile, needle-shaped crystals 3
• Granulomatous inflammation present in 98% of histologically confirmed cases 4
• Biopsy is rarely necessary—diagnosis is primarily clinical with laboratory correlation 1, 6

Critical Pitfalls to Avoid

• Do not wait for symptoms to begin calcium monitoring—hypercalcemia is asymptomatic initially but can rapidly become life-threatening 1, 2
• Do not stop monitoring at 1 month—hypercalcemia can develop up to 7 weeks after SCFN onset 5
• Do not rely on total calcium alone—ionized calcium is the more sensitive marker 1
• Do not assume normal calcium at presentation means no risk—86% of hypercalcemia cases were diagnosed within 28 days, but late presentations occur 1

Risk Stratification

Infants at highest risk for severe hypercalcemia include those with:

• Female sex (71% of SCFN cases) 2
• Large-for-gestational-age status (28% vs 8% in controls) 2
• History of therapeutic hypothermia for hypoxic-ischemic encephalopathy 2, 4
• Extensive skin involvement, particularly on the back 7
• Thrombocytopenia at presentation 2